Corcept settles patent litigation with Hikma; generic Korlym entry set for October 2034

CORCEPT THERAPEUTICS INC

Settlement with Hikma resolves patent litigation over generic Korlym in District of New Jersey.
Hikma granted right to sell generic Korlym in U.S. beginning October 1, 2034 or earlier under customary conditions.
Similar patent litigation against Teva Pharmaceuticals USA remains pending.
Settlement subject to court consent judgment and FTC/DOJ review.
CEO Belanoff noted the settlement allows focus on growing Korlym and developing cortisol modulator pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.